19th September 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

As per PGI Pharma leader, drug price regulation urgently needed

PGI Pharma head quoted that the price of a drug must be calculated on the basis of production cost and the drug packaging must contain MRP (Maximum Retail Price) and purchase price so that the profit margin is shown on it.

Jagsonpal Pharmaceuticals allows 10.47 Lakh stock options

The company under Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022 has granted 10,47,920 employee stock options at an exercise price of Rs. 235 per option.

Over 100 jobs lost as 100-year-old pharma unit in Chheharta closes

The termination of Mehta Pharmaceuticals unit in Chheharta has led to 100 employees being jobless. The unit was involved in the manufacturing of API (Active Pharmaceutical Ingredient) from herbal extracts.

It's misleading to claim drugs dropped from NLEM due to adverse effects like cancer

Government official sources have stated that the criteria for the addition or deletion of products in the NLEM is based on many factors and the decisions to drop some medicines off the list have not been taken over the presence of side effects or cancer concerns.

Novavax requests updated EUL from WHO for Nuvaxovid

Novavax has announced the submission of a request to WHO (World Health Organization) to renew the EUL (Emergency Use Listing) of Nuvaxovid vaccine indicated to be administered as a booster dose to prevent COVID-19 in adults aged 18 and older.

US FDA gives nod to Bluebird Bio's gene therapy

The company received an approval for its gene therapy “SKYSONA” for a rare neurological disorder. The therapy is expected to be made available commercially by the end of 2022 through a limited number of qualified treatment centers across the US.

US FDA clears Inversago pharma 's IND application for a phase II study

The clinical stage biotech company has received clearance from US regulatory body for its IND (Investigational New Drug) application for a phase II study in DKD (Diabetic Kidney Disease) for INV-202, which is the company’s lead program.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?